Introduction to Measles, Mumps and Rubella Vaccines Market
Measles, mumps and rubella are three common contagious airborne diseases that are caused by virus, transmitted by sneezing and coughing of an infected person, which can arise to serious complications or death. Vaccines of these diseases are sold as attenuated viral vaccines, manufactured in a lyophilized formulation, which requires reconstitution with water for injection diluent and are available in two forms i.e. monovalent as well as combinational vaccines. Combinational MMR vaccines comprise of mixture of two or more viral strains. These vaccines are administered by subcutaneous injection to children as well as adults. It is mostly administered to children aged 1 year and second dosage can be administered as early as one month after the first dosage. According to Center for Disease Control and Prevention (CDC), two doses of MMR are 97% effective against measles and 88% effective against mumps.
Measles, Mumps and Rubella (MMR) causes cough, fever, rash, headache and severe complications such as inflammation of ovaries and testicles, deafness including death. To prevent birth defects due to rubella, pregnant women are vaccinated for MMR vaccines. The virus replicates in the respiratory tract and is transmitted to others via respiratory secretions through aerosolized droplets in closed areas such as schools and offices. The average appearance of the symptoms is 10-12 days after the infection, which is usually fever. However, the MMR vaccines should not be given to individuals who are on immunosuppressant as the virus can replicate and cause infections. Disease indication, included in the vaccines market include influenza, pneumococcal disease, Diphtheria, Tetanus and Pertussis (DTP), rotavirus, hepatitis, polio, varicella, meningococcal disease, MMR, Human Papilloma Virus (HPV) infection, and others. High incidence of pneumococcal infections is driving the growth of this market.
Market Size and Forecast
The market is observing significant growth on account of high incidences of pneumococcal infections and increasing government and non-government initiatives for vaccine R&D activities. The key segments for MMR vaccinations include vaccine manufacturers, vaccine research institutions, clinical laboratories, healthcare centers, vaccine product distributors, bulk purchasing organizations, vaccine raw material suppliers, immunization centers, hospitals and laboratories, biotechnology and pharmaceutical firms.
The WHO reported a 300% increase in measles cases in the first three months of 2019 compared with the same time last year. An estimated 7 million people were affected by the measles in 2016. The global measles deaths decreased 84%, dropping to 89,780 in 2016 from 550,100 in 2000.
Get more information on this report: Download Sample PDF
Alliances in order to Improve Vaccination Programs
Vaccine manufacturers are focusing on partnering with organizations such as WHO, UNICEF and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines. In spite of several governmental initiatives, measles is leading cause of death among young children. Thus, increase in success rate of vaccination schemes depends on government initiatives of each country.
Rising Air Pollution
Rising air pollution levels owing to growing industrialization is leading to propel the airborne diseases globally such as measles which is a significant airborne disease. Initial symptoms related to this disease include fever, cough, redness in the eyes and running nose coupled with rashes in the body.
Reactions Related To Vaccinations
Side effects related to vaccinations could be a major factor restraining growth of the MMR vaccine market. For instance, in 1998, Japan stopped using trivalent combinational measles, mumps, and rubella vaccine owing to outbreak of non-viral meningitis and other damaging side effects which will restrict the MMR vaccine market growth. Moreover, high cost of single dosage of vaccine is another restraining factor for the market growth. Limited number of vaccines, stringent manufacturing and approval criteria along with gap between demand and supply during disease outbreak, and special storage and handling leading to high cost of measles, mumps and rubella vaccines are other factors affecting growth of the market.
Our-in depth analysis of the global measles, mumps and rubella market includes the following segments:
By Product Type
- Combinational (Divalent, Trivalent and Others)
By End Users
- Healthcare Centers
On the basis of regional analysis, the global MMR vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America region is the largest consumer. Growth in this region is primarily driven by government initiatives for immunization against diseases such as influenza and HPV. Asia Pacific is expected to expand at a high CAGR driven by government mandates and free immunization programmes against measles. Latin America and Middle East & Africa are expected to showcase significant growth driven by low cost of vaccinations. The cost of measles vaccinations is less than USD 1 in these regions.
The global MMR vaccine market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Prominent Players in the Market:
- CSL Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Emergent BioSolutions, Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson Pvt. Ltd.
- Sanofi Pasteur
- Novartis International AG
- Bavarian Nordic A/S
- JC Medical
- MedImmune, LLC
- Merck & Co. Inc.
- China National Biotec Group Comp. Ltd.